Immunodeficiency Diseases
📧 Sign up to get email alerts when something new happens for Immunodeficiency Diseases.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-20EMA Authorised: Xolremdi (mavorixafor) — Norgine B.V.
Xolremdi (mavorixafor) has been authorised in the EU for primary immunodeficiency diseases by Norgine B.V. (orphan medicine).
-
EMA approval · 2026-07-07EMA Authorised: Xolremdi (mavorixafor) — Norgine B.V.
EMA authorised Xolremdi (mavorixafor) by Norgine B.V. for primary immunodeficiency diseases (orphan medicine).
-
EMA approval · 2026-02-11EMA Authorised: HyQvia (human normal immunoglobulin) — Baxalta Innovations GmbH
EMA authorised HyQvia, a subcutaneous immunoglobulin product with recombinant human hyaluronidase, from Baxalta Innovations GmbH for immunod…
-
EMA approval · 2025-11-24EMA Authorised: Hizentra (human normal immunoglobulin (SCIg)) — CSL Behring GmbH
EMA authorised Hizentra, a subcutaneous immunoglobulin product, by CSL Behring, for immunologic deficiency syndromes related to primary immu…